1ST Biotherapeutics and D&D Pharmatech have secured a U.S. patent for NLY02, an oral small molecule in development for neurodegenerative diseases including Parkinson’s and Alzheimer’s, the companies said Wednesday.
The drug targets RIPK2, a signaling protein linked to neuroinflammation. In preclinical Parkinson’s models, NLY02 reduced inflammation and protected dopamine-producing neurons, which the companies say suggests early potential as a disease-modifying therapy.
“Through close collaboration, we’ve identified a previously unrecognized pathogenic mechanism in neurodegenerative disease and discovered a first-in-class candidate to address it,” said D&D Pharmatech CEO Lee Seul-ki.
The partners have been co-developing NLY02 since 2018, with 1ST Bio leading compound optimization and safety work, while D&D has handled clinical strategy. The companies said they are also in ongoing partnership discussions with global pharmaceutical firms.
Related articles
- D&D Pharmatech’s GLP-1/glucagon dual agonist hits primary endpoint in MASH phase 2
- Metsera’s long-acting obesity drug sheds 8.4% weight in phase 1, fueling once-monthly GLP-1 combo plan
- D&D Pharmtech scores US patent for MASH drug candidate DD01
- D&D Pharmatech completes US phase 2 dosing of MASH drug, eyes June data release